Psychiatric assessment
We review diagnosis, prior antidepressant treatment, medical history, medications, substance-use risk, blood pressure considerations, and treatment goals.
ESKETAMINE • SPRAVATO®
A monitored treatment pathway
for treatment-resistant depression.
Spravato® is intranasal esketamine. CA Cortex evaluates candidacy and provides treatment within a structured clinical setting when medically appropriate.
HOW THE PROGRAM WORKS
Evaluation, administration, monitoring.
Supervised treatment
Spravato® is self-administered under healthcare supervision in a certified treatment setting according to prescribing and REMS requirements.
Observation & follow-up
Patients are monitored after dosing, including for sedation, dissociation, and blood-pressure changes, and are discharged only when clinically appropriate.